RxDoctor Payments Data

Thomas Quinn, MD

Cardiovascular Disease · Palos Heights, ILNPI 1770502205

Payments from drug & device makers

$854in general payments, 2019–2025

Across 14 payments — averaging $61.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$284
  • Edwards Lifesciences$245
  • United Therapeutics Corporation$125
  • Boston Scientific$32
  • Heartflow, Inc.$31
  • Actelion Pharmaceuticals US, Inc.$27
  • plus $110 from 5 others

What the payments were for

  • Food & beverage$854100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$854 in reported general payments places this provider in the 35th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$171,190
Medicare patients
2,307
Services billed
4,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban327$436,772
XareltoRivaroxaban170$191,306
EntrestoSacubitril/Valsartan64$67,161
JardianceEmpagliflozin56$61,473
MultaqDronedarone Hcl24$35,869
Repatha SureclickEvolocumab16$15,585
Metoprolol Succinate545$11,020
Praluent PenAlirocumab13$8,224
Atorvastatin Calcium768$8,219
Amlodipine Besylate350$4,064
Valsartan122$3,951
Lisinopril290$2,943
Rosuvastatin Calcium180$2,484
Potassium Chloride177$2,457
Losartan Potassium212$2,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$21$191,306170 claims
NovartisEntresto$23$67,16164 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Palos Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →